Madison, Wisconsin-based Propeller Health has secured two new FDA clearances for new sensors that are designed to work with two particular inhalers on the market: the Diskus inhaler from GlaxoSmithKline and the Respimat inhaler from Boehringer Ingelheim. Unlike previous FDA clearances for Propeller, the new clearances actually allow Propeller to market its new devices as improving — not just tracking — medication adherence.
“From a business standpoint, these are really important medications because they’re widely used and they’re so important in the daily management of COPD,” Propeller CEO David Van Sickle told MobiHealthNews. “So bringing them on to our platform and the people who are using them to manage their condition has been an important goal with us for a while.”
Propeller’s previous sensor worked with a standard metered-dose inhaler (MDI) and it was able to deduce when the inhaler was being activated through mechanical means. For these more tightly designed inhalers, there’s “a lot more electronics involved” Van Sickle said.
“What we’ve done is put a lot of work into engineering a solution that doesn’t require the person to do anything, but then uses a lot of electronic means to understand when those medications are delivered,” he said. “A lot of different sensors are used to measure the actuation when there isn’t a simple linear path of force that we can monitor like we could with the MDI.” Keep reading>>